Exosome engineering has emerged as a promising frontier in biotechnology and precision medicine due to exosomes' unique ability to mediate intercellular communication and deliver bioactive molecules with high biocompatibility and low immunogenicity. Exosomes are nanosized extracellular vesicles secreted by cells that naturally transport proteins, lipids, RNA, and signaling molecules between tissues. Recent advances in molecular and cellular bioengineering have enabled the modification of exosomes for targeted therapeutic delivery, vaccine development, regenerative medicine, and diagnostic applications. Engineering strategies include genetic modification of donor cells, surface display of targeting ligands, cargo loading of therapeutic proteins or nucleic acids, and enhancement of exosome biogenesis and secretion. These engineered exosomes offer significant advantages over synthetic nanoparticles owing to their intrinsic stability, tissue compatibility, and ability to cross biological barriers. Furthermore, exosome-based platforms are being explored to develop virus-like particles, precision drug delivery systems, and cell-free therapeutics for cancer, infectious diseases, and inflammatory disorders. Despite challenges in large-scale production, purification, and standardization, exosome engineering is a rapidly evolving field with substantial translational potential for next-generation biomanufacturing and personalized medicine.

Engineering Precision Biotherapeutics

We are working on exosome engineering to develop recombinant protein-loaded exosomes for oral and systemic delivery. Engineered exosomes carrying recombinant human Factor VIII have demonstrated promising bioactivity and stability for potential treatment of Hemophilia A. The use of membrane localization signals and hybrid secretory targeting systems has further improved efficient loading of therapeutic proteins into exosomal lumen while preserving protein functionality. Detailed characterization through dynamic light scattering, transmission electron microscopy, flow cytometry, and exosome-specific molecular markers has validated the purity and structural integrity of engineered exosomes.

Milk-derived exosomes from transgenic livestock represent a promising strategy for cost-effective and scalable production of orally deliverable biologics. These developments position exosome engineering at the intersection of nanotechnology, synthetic biology, and precision medicine, with broad applications in drug delivery, regenerative medicine, cancer therapeutics, vaccine development, and cell-free therapeutics. Despite challenges related to large-scale purification, standardization, and regulatory approval, exosome engineering continues to evolve as a highly promising platform for next-generation biomedical applications.

Developing a Safe Vaccine Candidate

Virus-like particles (VLPs) are self-assembling nanostructures that mimic viral architecture without containing infectious genetic material, making them highly attractive for vaccine and delivery applications. However, conventional production platforms (yeast, insect, mammalian systems) often suffer from limitations in scalability, structural fidelity, and post-translational modification.

Exosomes, a subclass of extracellular vesicles (30–150 nm), are naturally secreted by cells and play critical roles in intercellular communication. Importantly, exosomes share physical similarities with enveloped viruses, including lipid bilayer composition and the use of the host ESCRT machinery for budding. This overlap has led to the emerging concept that exosomes and viruses are “intertwined entities” exploiting similar cellular pathways.

Recent studies demonstrate that exosomes can mediate viral protein transfer and even facilitate viral infection pathways, highlighting their inherent compatibility with viral structural components. Additionally, engineered exosomes exhibit high cargo-loading capacity, biocompatibility, and tissue penetration, making them promising platforms for nanomedicine. Advances in exosome engineering have enabled efficient encapsulation of therapeutic biomolecules, including proteins and nucleic acids, thereby further supporting their use as modular delivery systems. Moreover, exosomes show more stability between -80 °C to 4 °C and can also be lyophilized.

Collectively, these findings support the hypothesis that exosomes can be repurposed as biologically derived scaffolds for VLP generation (exo-VLPs), combining viral mimicry with endogenous delivery efficiency.